Flavonoids quercetin, dihydroquercetin (taxifolin): antioxidant and anti-ischemic effects, possibility of application in cardiology

DOI: https://doi.org/10.29296/25877305-2023-06-07
Issue: 
6
Year: 
2023

Professor D. Dedov(1, 2), MD; O. Usoltseva(3), Candidate of Medical Sciences
1-Tver State Medical University,
2-Tver Regional Clinical Cardiology Centre
3-Irkutsk State Medical University, Irkutsk, Russia

Objective. Determination of the place of flavonoids quercetin and dihydroquercetin as a preventive and auxiliary agent in the treatment of cardiovascular diseases. Material and methods. The analysis of literature data was carried out, in which the results of studies on the use of flavonoids quercetin, dihydroquercetin (taxifolin) in animal experiments and in patients with cardiovascular diseases were presented, as well as data from experimental laboratory studies were analyzed. Results and discussion. Flavonoids had antioxidant, antiradical, vasoprotective, antiplatelet, anti-inflammatory effects. They slow down the development of atherosclerosis and cardiovascular diseases, and are also a means of preventing fatal cardiovascular complications. The antihypertensive, anti-ischemic, antiarrhythmic, hypolipidemic, antiplatelet effect of quercetin and dihydroquercetin has been shown. The possibility of using dihydroquercetin in the complex treatment of patients with arterial hypertension is shown. The high efficiency of the drug Bio Dihydroquercetin, which is distinguished by a special author's production technology, and is a highly active dihydroquercetin, of natural origin with proven efficacy and safety, was noted. Taking dihydroquercetin is associated with a decrease in blood viscosity, a decrease in aggregation, an improvement in the deformability of red blood cells, as well as an improvement in endothelial function and tissue perfusion. Conclusions. Flavonoids quercetin, dihydroquercetin (Dihydroquercetin) have antioxidant, vasodilator, hypotensive, antiplatelet, hypolipidemic, anti-ischemic, anti-inflammatory effects. They can be used in the comprehensive prevention and treatment of patients with cardiovascular diseases.
Keywords: 
flavonoids
quercetin
dihydroquercetin
taxifolin
dihydroquercetin
antioxidant
antioxidant
anti-ischemic
antiplatelet
anti-inflammatory effect
cardiology
endothelial dysfunction
metabolic therapy.

References: 
  1. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008; 585 (2–3): 325–37. DOI: 10.1016/j.ejphar.2008.03.008
  2. Agrawal K., Chakraborty P., Dewanjee S. et al. Neuropharmacological interventions of quercetin and its derivatives in neurological and psychological disorders. Neurosci Biobehav Rev. 2023; 144: 104955. DOI: 10.1016/j.neubiorev.2022.104955
  3. D'Andrea G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia. 2015; 106: 256–71. DOI: 10.1016/j.fitote.2015.09.018
  4. Терехов Р.П. Влияние фазового состояния на физико-химические, технологические и биофармацевтические параметры дигидрокверцетина. Дисс. … канд. мед. наук. М., 2021; 173 с. [Terekhov R.P. Influence of phase state on physicochemical, technological and biopharmaceutical parameters of dihydroquercetin. Diss. … kand. med. nauk. M., 2021; 173 p. (in Russ.)].
  5. Селиванова И.А. Терехов Р.П. Инженерия кристаллов дигидрокверцетина. Химико-фармацевтический журнал. 2019; 53 (11): 53–7 [Selivanova I.A. Terekhov R.P. Engineering of dihydroquercetin crystals. Khimiko-Farmatsevticheskii Zhurnal. 2019; 53 (11): 53–7 (in Russ.)]. DOI: 10.30906/0023-1134-2019-53-11-53-57
  6. Тюкавкина Н.А., Руленко И.А., Колесник Ю.А. Дигидрокверцетин – новая антиоксидантная и биологически активная пищевая добавка. Вопросы питания. 1997; 6: 12–5 [Tyukavkina N.A., Rulenko I.A., Kolesnik Yu.A. Dihydroquercetin is a new antioxidant and dietary supplement. Voprosy pitaniya. 1997; 6: 12–5 (in Russ.)].
  7. Плотников М.Б., Логвинов С.В., Пугаченко Н.В. и др. Церебропротекторные эффекты смеси диквертина и аскорбиновой кислоты. Фармакология и токсикология. 2000; 130 (11): 543–7 [Plotnikov M.B., Logvinov S.V., Pugachenko N.V. et al. Cerebroprotective effects of a mixture of diquertin and ascorbic acid. Farmakologiya i toksikologiya. 2000; 130 (11): 543–7 (in Russ.)].
  8. Дедов Д.В. Дигидрокверцетин: фармакологические свойства, возможность применения препарата в клинической практике. Врач. 2022; 33 (10): 78–80 [Dedov D. Dihydroquercetin: pharmacological properties, possibility of using the drug in clinical practice. Vrach. 2022; 33 (10): 78–80 (in Russ.)]. DOI: 10.29296/25877305-2022-10-16
  9. Абрашина И.В. и др. Физико-химические особенности и биоактивность нативных флавоноидов на примере кверцетина и дигидрокверцетина. XLVII Огаревские чтения: мат-лы научн. конф.: в 3 ч. М., 2019; с. 323–30 [Abrashina I.V. et al. Physico-chemical features and bioactivity of native flavonoids as exemplified by quercetin and dihydroquercetin. XLVII Ogarevskie chteniya: mat-ly nauchn. konf.: v 3 ch. M.: 2019; рр. 323–30 (in Russ.)].
  10. Владимиров Ю.А. и др. Дигидрокверцетин (таксифолин) и другие флавоноиды как ингибиторы образования свободных радикалов на ключевых стадиях апоптоза. Биохимия. 2009; 74 (3): 372–9 [Vladimirov Yu.A. et al. Dihydroquercetin (Taxifolin) and other flavonoids as inhibitors of free radical formation at key stages of apoptosis. Biokhimiya. 2009; 74 (3): 372–9 (in Russ.)].
  11. Бабкин В.А., Остроухова Л.А., Левчук А.А. и др. Влияние условий экстракции на выход нативного дигидрокверцетина, содержащего более 97% (+)-2R,3R-транс-изомера. Химико-фармацевтический журнал. 2017; 51 (1): 39–41 [Babkin V.A., Ostroukhova L.A., Levchuk A.A. et al. Effects of extraction conditions on the yield of native dihydroquercetin containing more than 97% (+)-2R,3R-trans isomer. Khimiko-Farmatsevticheskii Zhurnal. 2017; 51 (1): 39–41. (in Russian)]
  12. Patel R.V., Mistry B.M., Shinde S.K. et al. Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem. 2018; 155: 889–904. DOI: 10.1016/j.ejmech.2018.06.053
  13. Усольцева О.Н., Колесников Д.Н., Потупчик Т.В. Оценка качества и биологической активности биодигидрокверцетина. Фармация. 2022; 71 (8): 5–14 [Usoltceva O.N., Olennikov D.N., Potupchik T.V. Evaluation of the quality and biological activity of BioDihydroquercetin. Pharmacy. 2022; 71 (8): 5–14 (in Russ.)]. DOI: 10/29296/25419218-2022-08-01
  14. Bondonno N.P., Lewis J.R., Blekkenhorst L.C. et al. Association of flavonoids and flavonoid-rich foods with all-cause mortality: The Blue Mountains Eye Study. Clin Nutr. 2020; 39 (1): 141–50. DOI: 10.1016/j.clnu.2019.01.004
  15. Zou H., Ye H., Kamaraj R. et al. A review on pharmacological activities and synergistic effect of quercetin with small molecule agents. Phytomedicine. 2021; 92: 153736. DOI: 10.1016/j.phymed.2021.153736
  16. Grewal A.K., Singh T.G., Sharma D. et al. Mechanistic insights and perspectives involved in neuroprotective action of quercetin. Biomed Pharmacother. 2021; 140: 111729. DOI: 10.1016/j.biopha.2021.111729
  17. Maaliki D., Shaito A.A., Pintus G. et al. Flavonoids in hypertension: a brief review of the underlying mechanisms. Curr Opin Pharmacol. 2019; 45: 57–65. DOI: 10.1016/j.coph.2019.04.014
  18. Jiang W., Wei H., He B. Dietary flavonoids intake and the risk of coronary heart disease: a dose-response meta-analysis of 15 prospective studies. Thromb Res. 2015; 135 (3): 459–63. DOI: 10.1016/j.thromres.2014.12.016
  19. Papakyriakopoulou P., Velidakis N., Khattab E. et al. Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases. Pharmaceuticals (Basel). 2022; 15 (8): 1019. DOI: 10.3390/ph15081019
  20. Akhlaghi M., Bandy B. Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2009; 46 (3): 309–17. DOI: 10.1016/j.yjmcc.2008.12.003
  21. Faggio C., Sureda A., Morabito S. et al. Flavonoids and platelet aggregation: A brief review. Eur J Pharmacol. 2017; 807: 91–101. DOI: 10.1016/j.ejphar.2017.04.009
  22. Siasos G., Tousoulis D., Tsigkou V. et al. Flavonoids in atherosclerosis: an overview of their mechanisms of action. Curr Med Chem. 2013; 20 (21): 2641–60. DOI: 10.2174/0929867311320210003
  23. Sebastian R.S., Wilkinson Enns C., Goldman J.D. et al. A New Database Facilitates Characterization of Flavonoid Intake, Sources, and Positive Associations with Diet Quality among US Adults. J Nutr. 2015; 145 (6): 1239–48. DOI: 10.3945/jn.115.213025
  24. Хабибулина М.М., Шамилов М.Д. Влияние метаболической терапии на состояние сосудов при эстрогенодефиците и артериальной гипертензии. Врач. 2023; 34 (2): 80–5 [Khabibulina M., Shamilov M. Evaluation of the effect of metabolic therapy on the state of blood vessels in estrogen deficiency and hypertension. Vrach. 2023; 34 (2): 80–5 (in Russ.)]. DOI: 10.29296/25877305-2023-02-18
  25. Хабибулина М.М., Шамилов М.Д. Влияние метаболической терапии на состояние сосудистого русла при дислипидемии в пременопаузе. Врач. 2023; 34 (5): 83–7 [Khabibulina M., Shamilov M. Effect of metabolic therapy on the state of the vascular bed in premenopausal dyslipidemia. Vrach. 2023; 34 (5): 83–8 (in Russ.)]. DOI: 10.29296/25877305-2023-05-15
  26. Mink P.J., Scrafford C.G., Barraj L.M. et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr. 2007; 85 (3): 895–909. DOI: 10.1093/ajcn/85.3.895
  27. Zhou F., Gu K., Zhou Y. Flavonoid intake is associated with lower all-cause and disease-specific mortality: The National Health and Nutrition Examination Survey 2007-2010 and 2017-2018. Front Nutr. 2023; 10: 1046998. DOI: 10.3389/fnut.2023.1046998
  28. Kim Y., Je Y. Flavonoid intake and mortality from cardiovascular disease and all causes: A meta-analysis of prospective cohort studies. Clin Nutr ESPEN. 2017; 20: 68–77. DOI: 10.1016/j.clnesp.2017.03.004
  29. Perez-Vizcaino F., Duarte J. Flavonols and cardiovascular disease. Mol Aspects Med. 2010; 31 (6): 478–94. DOI: 10.1016/j.mam.2010.09.002
  30. Jia J.Y., Zang E.H., Lv L.J. et al. Flavonoids in myocardial ischemia-reperfusion injury: Therapeutic effects and mechanisms. Chin Herb Med. 2020; 13(1): 49–63. DOI: 10.1016/j.chmed.2020.09.002
  31. Larson A.J., Symons J.D., Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr. 2012; 3 (1): 39–46. DOI: 10.3945/an.111.001271
  32. Edwards R.L., Lyon T., Litwin S.E. et al. Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007; 137 (11): 2405–11. DOI: 10.1093/jn/137.11.2405
  33. Grande F., Parisi O.I., Mordocco R.A. et al. Quercetin derivatives as novel antihypertensive agents: Synthesis and physiological characterization. Eur J Pharm Sci. 2016; 82: 161–70. DOI: 10.1016/j.ejps.2015.11.021
  34. Romero M., Jiménez R., Sánchez M. et al. Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PKC. Atherosclerosis. 2009; 202 (1): 58–67. DOI: 10.1016/j.atherosclerosis.2008.03.007
  35. Burak C., Wolffram S., Zur B. et al. Effect of alpha-linolenic acid in combination with the flavonol quercetin on markers of cardiovascular disease risk in healthy, non-obese adults: A randomized, double-blinded placebo-controlled crossover trial. Nutrition. 2019; 58: 47–56. DOI: 10.1016/j.nut.2018.06.012
  36. Granger D.N., Kvietys P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015; 6: 524–51. DOI: 10.1016/j.redox.2015.08.020
  37. Wang H., Jiang W., Hu Y. et al. Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression. Phytomedicine. 2021; 93: 153774. DOI: 10.1016/j.phymed.2021.153774
  38. Tan X., Xian W., Li X. et al. Mechanisms of Quercetin against atrial fibrillation explored by network pharmacology combined with molecular docking and experimental validation. Sci Rep. 2022; 12 (1): 9777. DOI: 10.1038/s41598-022-13911-w
  39. Zhou Y., Suo W., Zhang X. et al. Roles and mechanisms of quercetin on cardiac arrhythmia: A review. Biomed Pharmacother. 2022; 153: 113447. DOI: 10.1016/j.biopha.2022.113447
  40. da Purificação N.R.C., Garcia V.B., Frez F.C.V. et al. Combined use of systemic quercetin, glutamine and alpha-tocopherol attenuates myocardial fibrosis in diabetic rats. Biomed Pharmacother. 2022; 151: 113131. DOI: 10.1016/j.biopha.2022.113131
  41. Popiolek-Kalisz J., Fornal E. The Effects of Quercetin Supplementation on Blood Pressure – Meta-Analysis. Curr Probl Cardiol. 2022; 47 (11): 101350. DOI: 10.1016/j.cpcardiol.2022.101350
  42. Guo H., Zhang X., Cui Y. et al. Taxifolin protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Toxicol Appl Pharmacol. 2015; 287 (2): 168–77. DOI: 10.1016/j.taap.2015.06.002
  43. Hooper L., Kroon P.A., Rimm E.B. et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008; 88 (1): 38–50. DOI: 10.1093/ajcn/88.1.38
  44. Williamson G., Kay C.D., Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. Compr Rev Food Sci Food Saf. 2018; 17 (5): 1054–112. DOI: 10.1111/1541-4337.12351
  45. Wang T.Y., Li Q., Bi K.S. Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. Asian J Pharm Sci. 2018; 13 (1): 12–23. DOI: 10.1016/j.ajps.2017.08.004
  46. Perez-Vizcaino F., Fraga C.G. Research trends in flavonoids and health. Arch Biochem Biophys. 2018; 646: 107–12. DOI: 10.1016/j.abb.2018.03.022